Skip to content
DataLookout
Menu

NCT07885228

Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Overall response rate (ORR)
Timeframe: Day 28

Secondary (10)

Durable overall response (DOR) at Day 56
Best Overall Response (BOR)
Overall response rate (ORR)
Overall Survival (OS)
Failure-Free Survival (FFS)
Show 5 moreShow less
Relapse-Free Survival (RFS)
Disease Relapse Rate
Event-Free Survival (EFS)
Incidence of Chronic Graft-Versus-Host Disease (cGVHD)
Safety and Tolerability (TEAEs)

Arms and interventions

Jaktinib ArmExperimental

Eligible participants with Grade II-IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) will be assigned to this single group. All patients in this arm will receive Jaktinib treatment to evaluate its safety and clinical efficacy.

Drugs: Jaktinib

Sites

24 sites in 1 country